CAPR · XBRL financial data

Capricor Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CAPR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	6,186	12,088*	4,907	3,971	2,262	11,131*	—	—	—	year only	—	—
Research and development	10,029	9,940*	11,101	12,505	11,808	14,555*	18,916	22,047	20,359	23,133*	27,377	28,866
General and administrative	3,021	3,429*	4,072	3,058	3,464	4,273*	6,067	5,672	5,925	6,023*	9,396	14,079
Total operating expenses	13,050	13,369*	15,173	15,563	15,272	18,828*	24,983	27,719	26,284	29,156*	36,773	42,946
Operating income (loss)	(6,865)	(1,281)*	(10,266)	(11,591)	(13,010)	(7,698)*	(24,983)	(27,719)	(26,284)	(29,156)*	(36,773)	(42,946)
Interest expense	—	—	—	—	—	year only	—	—	—	year only	—	—
Income tax expense (benefit)	—	—	—	—	—	year only	0	2	—	year only	0	2
Net income (loss)	(6,391)	(762)*	(9,794)	(11,000)	(12,557)	(7,117)*	(24,392)	(25,911)	(24,571)	(30,171)*	(33,941)	(40,734)
Earnings per share, basic USD per share	(0.25)	(0.02)*	(0.31)	(0.35)	(0.38)	—	(0.53)	(0.57)	(0.54)	(0.62)*	(0.59)	(0.70)
Earnings per share, diluted USD per share	(0.25)	(0.02)*	(0.31)	(0.35)	(0.38)	—	(0.53)	(0.57)	(0.54)	(0.62)*	(0.59)	(0.70)
Weighted average shares, basic thousands of shares	25,818	30,664*	31,355	31,842	33,090	—	45,637	45,709	45,716	48,825*	57,434	57,926
Weighted average shares, diluted thousands of shares	25,818	30,664*	31,355	31,842	33,090	—	45,637	45,709	45,716	48,825*	57,434	57,926

Balance sheet

CSV

Fiscal quarters (CAPR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	8,985	14,695	6,215	10,688	68,377	11,287	28,795	23,241	19,510	287,847	105,421	20,935
Marketable securities	19,537	24,793	33,702	18,774	16,651	140,229	115,983	99,559	79,056	30,282	173,188	217,000
Prepaid and other current assets	458	996	1,126	837	385	1,501	1,414	1,266	2,327	4,752	4,479	4,193
Total current assets	29,527	50,855	41,412	30,669	85,823	163,385	146,251	124,127	100,952	322,940	283,089	242,128
Property and equipment, net	5,140	5,561	5,894	5,618	5,315	5,562	6,134	7,995	11,068	18,312	28,503	36,346
Right-of-use asset	2,217	2,050	1,845	1,671	1,494	1,313	1,128	939	13,930	13,538	13,159	88,615
Total assets	37,152	58,734	49,444	38,277	92,952	170,481	153,766	133,569	126,438	355,949	326,284	368,736
Accounts payable	—	—	—	—	—	3,284	5,254	4,812	2,719	1,655	3,928	3,080
Accrued liabilities	—	—	—	—	—	4,908	4,241	7,359	9,932	15,558	10,528	16,392
Total current liabilities	32,927	31,270	26,384	22,355	20,476	21,026	22,337	28,397	28,148	35,837	33,637	32,961
Lease liability, non-current	1,684	1,487	1,249	1,044	835	616	407	195	14,423	14,320	13,944	89,556
Total liabilities	38,940	36,133	31,010	26,775	24,687	25,019	26,121	28,592	42,571	50,157	47,581	122,517
Accumulated deficit	(158,605)	(159,367)	(169,161)	(180,161)	(192,718)	(199,835)	(224,226)	(250,137)	(274,708)	(304,878)	(338,820)	(379,553)
Total stockholders' equity	(1,788)	22,601	18,435	11,502	68,265	145,462	127,645	104,977	83,867	305,792	278,703	246,219
Total liabilities and equity	37,152	58,734	49,444	38,277	92,952	170,481	153,766	133,569	126,438	355,949	326,284	368,736
Common shares outstanding (cover page) thousands of shares	30,793	31,400	31,811	32,539	45,470	45,676	45,708	45,717	45,718	57,511	57,912	58,139

Cash flows

CSV

Fiscal quarters (CAPR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6,391)	(762)*	(9,794)	(11,000)	(12,557)	(7,117)*	(24,392)	(25,911)	(24,571)	(30,171)*	(33,941)	(40,734)
Stock-based compensation	1,717*	1,862*	3,265	2,153*	2,051*	2,296*	—	—	—	—	—	—
Depreciation and amortization	276*	308*	331	357*	361*	376*	405	486*	495*	503*	535	562*
Net cash from operating activities	(8,795)*	(11,594)*	(1,268)	(12,288)*	(11,642)*	(14,796)*	(6,434)	(20,122)*	(19,689)*	(23,567)*	(29,255)	(31,485)*
Purchases of property and equipment	269*	559*	609	60*	9*	489*	896	288*	56*	1,665*	5,122	4,063*
Net cash from investing activities	7,721*	(5,863)*	(9,502)	14,695*	2,005*	(123,382)*	23,891	14,549*	15,951*	43,088*	(154,642)	(48,758)*
Proceeds from issuing common stock	221*	23,164*	2,290	1,986*	67,206*	80,840*	—	—	—	year only	—	—
Net cash from financing activities	221*	23,167*	2,290	2,067*	67,327*	81,088*	50	20*	7*	248,815*	1,471	(4,243)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Capricor Therapeutics	20,935	not reported	(31,485)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Cryoport	269,267	48,971	1,131*	50.6M	—	Q2 FY26 10-QJun 30, 2026
REGENXBIO	36,487	108,019	(62,238)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
CytoDyn	16,359	not reported	(7,726)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Cronos Group	467,019	53,007	24,010*	368.4M	—	Q2 FY26 10-QJun 30, 2026
CytomX Therapeutics	17,224	1,418	(18,068)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Oruka Therapeutics	268,470	not reported	(33,145)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.